Novel immune signatures associated with dysplastic naevi and primary cutaneous melanoma in human skin.
Dendritic Cells
/ cytology
Disease Progression
Dysplastic Nevus Syndrome
/ metabolism
Gene Expression Profiling
Gene Expression Regulation, Neoplastic
Humans
Immune System
Immunotherapy
Interferon-gamma
/ metabolism
Interleukin-12 Subunit p35
/ metabolism
Melanoma
/ immunology
Nevus, Pigmented
/ metabolism
Skin
/ immunology
Skin Neoplasms
/ immunology
Suppressor of Cytokine Signaling 3 Protein
/ metabolism
T-Lymphocytes, Regulatory
/ cytology
Th1 Cells
/ cytology
Tumor Microenvironment
Melanoma, Cutaneous Malignant
exhausted T cell
immune checkpoints
immunoregulation
regulatory dendritic cell
tumor immunology
Journal
Experimental dermatology
ISSN: 1600-0625
Titre abrégé: Exp Dermatol
Pays: Denmark
ID NLM: 9301549
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
received:
27
06
2018
revised:
25
09
2018
accepted:
11
10
2018
pubmed:
17
10
2018
medline:
18
6
2020
entrez:
17
10
2018
Statut:
ppublish
Résumé
Dysplastic naevi (DN) are benign lesions with atypical features intermediate between that of common melanocytic naevi (CMN) and malignant melanoma (MM). Debate remains over whether DN represent progressive lesions from CMN. Through gene expression profiling and analysis of molecular gene signatures, our study revealed progressive increases in immune activation and regulation, along with pathways implicated in melanomagenesis, from CMN to DN to MM. Using criteria of 1.5-fold change and false discovery rate ≤0.05, we found differential expression of 7186 probes (6370 unique genes) with the largest difference detected between DN and MM from the standpoint of genomic melanoma progression. Despite progressive increases in the T-helper type 1 (Th1)-inducing gene (IL-12), RT-PCR indicated impaired Th1 or cytotoxic T-cell response (decreased IFN-γ) in MM. Concordantly, our results indicated progressive increases in molecular markers associated with regulatory T cells, exhausted T cells and tolerogenic dendritic cells, including detection of increased expression of suppressor of cytokine signalling 3 (SOCS3) in dendritic cells associated with MM. All together, our findings suggest that the increased immunosuppressive microenvironment of melanoma may contribute to unhampered proliferation of neoplastic cells. In addition, the detection of increased markers associated with tolerogenic dendritic cells in MM suggests that targeting these suppressive immune cell types may represent an alternative avenue for future immunotherapy.
Identifiants
pubmed: 30326165
doi: 10.1111/exd.13805
pmc: PMC6333525
mid: NIHMS993428
doi:
Substances chimiques
IL12A protein, human
0
Interleukin-12 Subunit p35
0
SOCS3 protein, human
0
Suppressor of Cytokine Signaling 3 Protein
0
Interferon-gamma
82115-62-6
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
35-44Subventions
Organisme : NCATS NIH HHS
ID : KL2 TR000151
Pays : United States
Organisme : NIH HHS
ID : KL2TR000151
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001866
Pays : United States
Organisme : Milstein Foundation
Pays : International
Organisme : NIH HHS
ID : UL1TR001866
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM007739
Pays : United States
Organisme : NIH HHS
ID : T32GM07739
Pays : United States
Informations de copyright
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Histol Histopathol. 2000 Jul;15(3):843-9
pubmed: 10963128
Mod Pathol. 2003 Aug;16(8):764-71
pubmed: 12920220
Int J Mol Med. 2003 Oct;12(4):597-601
pubmed: 12964041
J Immunol. 2006 Aug 1;177(3):1679-88
pubmed: 16849477
J Allergy Clin Immunol. 2007 May;119(5):1210-7
pubmed: 17472813
J Invest Dermatol. 2007 Oct;127(10):2391-8
pubmed: 17508019
Appl Immunohistochem Mol Morphol. 2007 Jun;15(2):160-4
pubmed: 17525627
Immunology. 2008 Oct;125(2):161-9
pubmed: 18397264
Cancer Res. 2008 Jul 1;68(13):5397-404
pubmed: 18593942
Immunol Rev. 2008 Aug;224:265-83
pubmed: 18759933
J Immunol. 2008 Nov 15;181(10):7420-7
pubmed: 18981165
J Exp Med. 2009 Jul 6;206(7):1457-64
pubmed: 19564351
Int J Cancer. 2010 Apr 15;126(8):1869-1881
pubmed: 19795447
Cancer Res. 2010 Jan 1;70(1):89-98
pubmed: 19996282
Histopathology. 2010 Jan;56(1):112-20
pubmed: 20055909
Nat Rev Cancer. 2010 Apr;10(4):232-3
pubmed: 20355252
Nature. 2010 Jul 1;466(7302):133-7
pubmed: 20596026
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Immunol Rev. 2011 May;241(1):206-27
pubmed: 21488899
Bioinformatics. 2011 Jun 15;27(12):1739-40
pubmed: 21546393
PLoS Comput Biol. 2011 Oct;7(10):e1002240
pubmed: 22028643
Nature. 2011 Nov 09;479(7374):547-51
pubmed: 22080947
J Invest Dermatol. 2012 Jun;132(6):1615-26
pubmed: 22402443
J Immunol. 2012 Aug 1;189(3):1182-92
pubmed: 22753940
BMC Neurol. 2012 Sep 18;12:95
pubmed: 22989378
Science. 2013 Feb 22;339(6122):959-61
pubmed: 23348503
Science. 2013 Feb 22;339(6122):957-9
pubmed: 23348506
Biochem Biophys Res Commun. 2014 Jan 3;443(1):56-61
pubmed: 24269818
J Invest Dermatol. 2014 May;134(5):1418-1427
pubmed: 24270662
Pharmaceuticals (Basel). 2013 Nov 11;6(11):1429-50
pubmed: 24287465
J Exp Med. 2014 Aug 25;211(9):1905-18
pubmed: 25113973
F1000Res. 2015 Jun 11;4:149
pubmed: 26236467
J Allergy Clin Immunol. 2015 Nov;136(5):1277-87
pubmed: 26316095
Front Immunol. 2015 Oct 19;6:528
pubmed: 26539195
N Engl J Med. 2015 Nov 12;373(20):1926-36
pubmed: 26559571
Cell Syst. 2015 Dec 23;1(6):417-425
pubmed: 26771021
Pathology. 2016 Feb;48(2):147-54
pubmed: 27020387
Oncotarget. 2016 May 3;7(18):26653-69
pubmed: 27049717
Nat Rev Cancer. 2016 Jun;16(6):345-58
pubmed: 27125352
PLoS One. 2016 May 06;11(5):e0155215
pubmed: 27152848
J Invest Dermatol. 2016 Oct;136(10):2030-2040
pubmed: 27377700
Hum Pathol. 2016 Nov;57:116-125
pubmed: 27473267
Semin Immunopathol. 2017 Feb;39(2):137-152
pubmed: 27888331
Ann Surg. 2018 Mar;267(3):495-503
pubmed: 28026832
Nature. 2017 May 11;545(7653):175-180
pubmed: 28467829
JCI Insight. 2017 May 4;2(9):null
pubmed: 28469092
Nat Commun. 2017 May 05;8:15081
pubmed: 28474673
Cell. 2017 Jun 29;170(1):127-141.e15
pubmed: 28666115
Front Immunol. 2017 Jun 30;8:753
pubmed: 28713377
Science. 2017 Sep 29;357(6358):1416-1420
pubmed: 28818973
J Am Acad Dermatol. 2017 Nov;77(5):938-945.e4
pubmed: 28864306
Science. 2017 Sep 29;357(6358):1358-1359
pubmed: 28963245
Ann Transl Med. 2017 Oct;5(19):386
pubmed: 29114544
Pathology. 2018 Jan;50(1):16-23
pubmed: 29132722
Nat Commun. 2017 Dec 7;8(1):1988
pubmed: 29215016
Nature. 2018 Jan 18;553(7688):351-355
pubmed: 29320480
Mol Biol Evol. 2018 May 1;35(5):1063-1077
pubmed: 29474580
Front Immunol. 2018 Mar 22;9:610
pubmed: 29623082
J Allergy Clin Immunol. 2018 Jun;141(6):2094-2106
pubmed: 29731129
Hum Pathol. 1984 Dec;15(12):1147-65
pubmed: 6500548
J Immunol. 1993 Sep 1;151(5):2667-75
pubmed: 8360485
J Cell Biol. 1993 Mar;120(5):1281-8
pubmed: 8436594
JAMA. 1997 May 14;277(18):1439-44
pubmed: 9145715
Ned Tijdschr Geneeskd. 1997 Oct 18;141(42):2010-4
pubmed: 9550752